title: Targeting head and neck squamous cell carcinoma using a novel fusion toxin-diphtheria toxin/HN-1.
abstract: The current treatment strategies, chemotherapy and radiation therapy being used for the management of cancer are deficient in targeted approach leading to treatment related toxicities and relapse. Contrarily, fusion toxins exhibit remarkable tumor specificity thus emerging as an alternative therapy for the treatment of cancer. Diphtheria toxin-HN-1 peptide (DT/HN-1) is a fusion toxin designed to target the head and neck squamous cell carcinoma (HNSCC). The aim of this study was to construct, characterize, and evaluate the cytotoxicity and specificity of DT/HN-1 fusion toxin against the HNSCC cells. The purified DT/HN-1 fusion toxin was characterized by SDS-PAGE and western blotting. Refolding of purified fusion toxins was monitored by fluorescence spectra and circular dichroism spectra. The activity of DT/HN-1 fusion toxin was demonstrated on various HNSCC cell lines by cell viability assay, cell proliferation assay, protein synthesis inhibition assay, apoptosis and cell cycle analysis. The fusion toxin DT/HN-1 demonstrated remarkably high degree of cytotoxicity specific to the HNSCC cells. The IC(50) of DT/HN-1 fusion toxin was ~1 to 5 nM in all the three HNSCC cell lines. The percentage apoptotic cells in DT/HN-1 treated UMB-SCC-745 cells are 16% compared to 4% in untreated. To further demonstrate the specific toxicity of DT/HN-1 fusion toxin towards the HNSCC cells we constructed, characterized and evaluated the efficacy of DT protein. The DT protein coding for only a fragment of diphtheria toxin without its native receptor binding domain failed to exhibit any cytotoxicity on all the cell lines used in this study thus establishing the importance of a ligand in achieving targeted toxicity. To evaluate the translocation ability of HN-1 peptide, an additional construct DTΔT/HN-1 was constructed, characterized and evaluated for its cytotoxic activity. The fusion toxin DTΔT/HN-1 deficient of the translocation domain of diphtheria toxin showed no cytotoxicity on all the cell lines clearly indicating the inability of HN-1 peptide to translocate catalytic domain of the toxin into the cytosol.
authors.affiliation: Stem Cell & Molecular Biology Laboratory, Department of Biotechnology, Indian Institute of Technology Madras, #201, Bhupat and Jyoti Mehta School of Biosciences Building, Chennai, 600036, India.
authors.forename: Sirisha
authors.initials: S
authors.lastname: Potala
authors.forename: Rama S
authors.initials: RS
authors.lastname: Verma
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000378:metabolism*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D003001:Cloning, Molecular; D004167:Diphtheria Toxin / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D020128:Inhibitory Concentration 50; D008024:Ligands; D016297:Mutagenesis, Site-Directed; D009842:Oligopeptides / Q000494:pharmacology*; D010957:Plasmids / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D004167:Diphtheria Toxin; C417565:HN-1 peptide; D008024:Ligands; D009842:Oligopeptides
references.citation: Protein Sci. 1994 Sep;3(9):1464-75
references.pmid: 7833808
references.citation: Mol Biol Rep. 2010 Oct;37(7):3541-5
references.pmid: 20182807
references.citation: J Clin Oncol. 2001 Jan 15;19(2):376-88
references.pmid: 11208829
references.citation: J Immunol Methods. 2003 Mar 1;274(1-2):77-82
references.pmid: 12609534
references.citation: Am J Hematol. 1998 May;58(1):87-90
references.pmid: 9590158
references.citation: FEBS Lett. 1997 Apr 7;406(1-2):157-61
references.pmid: 9109408
references.citation: Protein Eng. 2000 Aug;13(8):575-81
references.pmid: 10964987
references.citation: Br J Cancer. 2005 Apr 25;92(8):1341-8
references.pmid: 15846296
references.citation: Appl Biochem Biotechnol. 2010 Nov;162(5):1258-69
references.pmid: 20084469
references.citation: Drug Discov Today. 2008 Sep;13(17-18):807-15
references.pmid: 18678276
references.citation: Mol Biol Rep. 2009 May;36(5):861-9
references.pmid: 18418730
references.citation: Expert Rev Anticancer Ther. 2006 Jul;6(7):1111-8
references.pmid: 16831082
references.citation: Eur Arch Otorhinolaryngol. 2008 Jul;265 Suppl 1:S3-12
references.pmid: 18535834
references.citation: J Neurooncol. 2003 Oct;65(1):3-13
references.pmid: 14649881
references.citation: J Biol Chem. 1980 Nov 25;255(22):10717-20
references.pmid: 7000782
references.citation: Mol Biol Rep. 2010 Jun;37(5):2301-7
references.pmid: 19693697
references.citation: Clin Cancer Res. 2003 Feb;9(2):861-5
references.pmid: 12576460
references.citation: PLoS One. 2008;3(12):e3909
references.pmid: 19079542
references.citation: Curr Opin Immunol. 1999 Oct;11(5):570-8
references.pmid: 10508704
references.citation: Apoptosis. 2004 Jan;9(1):19-25
references.pmid: 14739595
references.citation: Nature. 1992 May 21;357(6375):216-22
references.pmid: 1589020
references.citation: Cancer. 2009 Mar 1;115(5):922-35
references.pmid: 19156911
references.citation: Infect Immun. 1976 Sep;14(3):742-51
references.pmid: 987022
references.citation: Klin Onkol. 2008;21(2):45-52
references.pmid: 19102211
references.citation: Cancer Res. 2000 Dec 1;60(23):6551-6
references.pmid: 11118031